211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting

Phase 1

Phase 2

211At-BC8-B10211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Sponsor:

Fred Hutchinson Cancer Center

Code:

NCT03670966

Conditions

Acute Lymphoblastic Leukemia in Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Acute Myeloid Leukemia in Remission

Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome With Excess Blasts

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10

Cyclophosphamide

Total-Body Irradiation

Peripheral Blood Stem Cell Transplantation

Bone Marrow Transplantation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Fred Hutchinson Cancer Center on 2025-02-05.